These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8451663)

  • 1. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids.
    Feldman S; Perry CS; Andrew M; Jones L; Moffitt JE; Lamb D; Meschievitz C
    South Med J; 1993 Mar; 86(3):269-75, 284. PubMed ID: 8451663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo-controlled trial of a pertussis-toxoid vaccine.
    Trollfors B; Taranger J; Lagergård T; Lind L; Sundh V; Zackrisson G; Lowe CU; Blackwelder W; Robbins JB
    N Engl J Med; 1995 Oct; 333(16):1045-50. PubMed ID: 7675047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acellular pertussis vaccination of 2-month-old infants in the United States.
    Pichichero ME; Francis AB; Blatter MM; Reisinger KS; Green JL; Marsocci SM; Disney FA
    Pediatrics; 1992 May; 89(5 Pt 1):882-7. PubMed ID: 1579399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.
    Englund JA; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Anderson EL
    Pediatrics; 1994 Jan; 93(1):37-43. PubMed ID: 8265321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of diphtheria-tetanus-two component acellular pertussis vaccines in United States and Japanese infants at 2, 4, and 6 months of age.
    Rothstein EP; Kamiya H; Nii R; Matsuda T; Bernstein HH; Long SS; Hosbach PH; Meschievitz CK
    Pediatrics; 1996 Feb; 97(2):236-42. PubMed ID: 8584384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
    Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
    Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA; King J; Law B; Mills E; Willems P
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
    Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
    Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 13 acellular pertussis vaccines: adverse reactions.
    Decker MD; Edwards KM; Steinhoff MC; Rennels MB; Pichichero ME; Englund JA; Anderson EL; Deloria MA; Reed GF
    Pediatrics; 1995 Sep; 96(3 Pt 2):557-66. PubMed ID: 7659476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children.
    Kimura M; Kuno-Sakai H; Sato Y; Kamiya H; Nii R; Isomura S; Horiuchi K; Kato T; Deguchi M; Saikusa H
    Am J Dis Child; 1991 Jul; 145(7):734-41. PubMed ID: 2058603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy.
    Long SS; Deforest A; Smith DG; Lazaro C; Wassilak GF
    Pediatrics; 1990 Mar; 85(3):294-302. PubMed ID: 2304782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial.
    Blennow M; Granström M; Jäätmaa E; Olin P
    Pediatrics; 1988 Sep; 82(3):293-9. PubMed ID: 3043367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of the reactogenicity of a three-component acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants.
    Shek LP; Khor ES; Tan GH; Low KT; Ong D; Roy J; Han HH; Bock HL; Lee BW
    Southeast Asian J Trop Med Public Health; 2003 Dec; 34(4):863-8. PubMed ID: 15115101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants.
    Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA
    Am J Dis Child; 1993 Mar; 147(3):295-9. PubMed ID: 8438811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of currently available Japanese acellular pertussis vaccines and future problems.
    Kamiya H; Nii R
    Tokai J Exp Clin Med; 1988; 13 Suppl():45-9. PubMed ID: 3273618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations.
    Deloria MA; Blackwelder WC; Decker MD; Englund JA; Steinhoff MC; Pichichero ME; Rennels MB; Anderson EL; Edwards KM
    Pediatrics; 1995 Sep; 96(3 Pt 2):592-4. PubMed ID: 7659483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.